Psammaplin A is primarily recognized for its potential in cancer research due to its ability to inhibit histone deacetylase (HDAC) and DNA methyltransferase (DNMT). These inhibitory properties make it a promising candidate for epigenetic therapy, which aims to reverse abnormal gene expression patterns in cancer cells. By targeting these enzymes, Psammaplin A can potentially reactivate tumor suppressor genes and inhibit cancer cell proliferation. Additionally, its dual inhibitory action on both HDAC and DNMT sets it apart from other compounds, offering a unique approach to epigenetic modulation. Beyond oncology, Psammaplin A has shown antimicrobial activity, particularly against certain bacterial and fungal strains, suggesting its utility in developing new antimicrobial agents. Research is also exploring its anti-inflammatory and antioxidant properties, which could be beneficial in treating chronic inflammatory diseases and reducing oxidative stress-related damage. Overall, Psammaplin A holds significant promise in multiple therapeutic areas, particularly in cancer treatment and antimicrobial development.